Kenneth, you asked a great question: “Could a virus alter the genetics of a host permanently…
R. Philip Bouchard

There was a time I owned CEGE stock but sold it after they spun off Abgenix which was eventually acquired by Amgen which I already had an investment in. Interesting history of virus commercialization for medicine, and a case study for successful phase II trial euphoria being a bad investment entry point.

Cell Genesys’ (CEGE) is a biotechnology company that develops cell-based cancer immunotherapies and oncolytic virus therapies. Its therapies are used to treat prostate cancer, pancreatic cancer, acute and chronic myelogenous leukemia, myelodysplastic syndrome, and recurrent bladder cancer. The stock has a market cap of $307 million. Its latest reported earnings were negative.